MEI Pharma Inc (MEIP) Rises A lot Today, Is Now One of The Best Performer

September 17, 2017 - By Henry Gaston

The stock of MEI Pharma Inc (NASDAQ:MEIP) is a huge mover today! The stock increased 4.17% or $0.11 on September 15, reaching $2.75. About 241,693 shares traded or 4.96% up from the average. MEI Pharma Inc (NASDAQ:MEIP) has risen 20.90% since September 17, 2016 and is uptrending. It has outperformed by 4.20% the S&P500.
The move comes after 8 months positive chart setup for the $97.52M company. It was reported on Sep, 17 by Barchart.com. We have $3.00 PT which if reached, will make NASDAQ:MEIP worth $8.78 million more.

Investors wait MEI Pharma Inc (NASDAQ:MEIP) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.17 EPS, down $0.05 or 41.67 % from last year’s $-0.12 same quarter earnings. MEI Pharma Inc’s Wall Street analysts see 41.67 % negative EPS growth, taking into account the $-0.12 EPS reproted in the previous quarter,

MEI Pharma Inc (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 6 by Stifel Nicolaus. As per Wednesday, August 2, the company rating was maintained by Oppenheimer. On Wednesday, May 31 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The rating was maintained by Oppenheimer with “Buy” on Wednesday, June 14. The stock of MEI Pharma Inc (NASDAQ:MEIP) has “Hold” rating given on Friday, September 4 by Wedbush.

More notable recent MEI Pharma Inc (NASDAQ:MEIP) news were published by: Prnewswire.com which released: “MEI Pharma Reports Fiscal Year 2017 Results” on September 05, 2017, also Prnewswire.com with their article: “MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for …” published on September 05, 2017, Nasdaq.com published: “MEI Pharma-Presage Biosciences on License Deal for Voruciclib” on September 06, 2017. More interesting news about MEI Pharma Inc (NASDAQ:MEIP) were released by: 247Wallst.com and their article: “Can MEI Pharma Rise Nearly 300%?” published on May 25, 2017 as well as Prnewswire.com‘s news article titled: “Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation …” with publication date: May 18, 2017.

MEI Pharma, Inc. is an oncology company. The company has market cap of $97.52 million. The Firm is focused on the clinical development of drugs and therapies for treatment of cancer. It has a 41.12 P/E ratio. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.